Guerrero A L, Bueno V, Hernández M T, Martín-Serradilla J I, Carrasco E, Cuadrado I
Unidad de Neurología, Hospital Río Carrión, Palencia, Spain.
Neurologia. 2003 Apr;18(3):146-8.
During recent years, different studies have proposed that apolipoprotein E e4 can be a predictor of progression in multiple sclerosis. We aim to evaluate these findings in our country.
We studied 42 patients with relapsing remitting or secondary progressive multiple sclerosis, and a disease duration of at least 2 years. We correlated the presence or absence of e4 allele with markers of progression such as age of onset and diagnosis, disease duration, number of relapses, EDSS at 1, 2, 5 and 10 years, progression index and relapse rate.
None of the parameters evaluated significantly correlate with e4 allele of the APOE.
In spite of the limitation due to the small number of patients studied, we cannot confirm that APOE e4 allele is a predictor of progression of disability in multiple sclerosis.
近年来，不同的研究表明载脂蛋白E e4可能是多发性硬化症病情进展的一个预测指标。我们旨在评估我国的这些研究结果。
我们研究了42例复发缓解型或继发进展型多发性硬化症患者，病程至少2年。我们将e4等位基因的有无与病情进展指标进行关联，如发病年龄、诊断年龄、病程、复发次数、1年、2年、5年和10年时的扩展残疾状态量表（EDSS）、进展指数和复发率。
所评估的参数均与APOE的e4等位基因无显著相关性。
尽管由于研究患者数量较少存在局限性，但我们不能证实APOE e4等位基因是多发性硬化症残疾进展的预测指标。
